Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D Lao

Showing results (31-40 of 86) with videos related to

Pageof 9
Sort By:
Frontiers in Immunology|July 25, 2022
Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/NivolumabVincent T Ma, Alahendra A Chamila Perera, Yilun Sun, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 13, 2004
Irreversible ototoxicity associated with difluoromethylornithineChristopher D Lao, Patricia Backoff, Lawrence I Shotland, et al.
BMC Complementary and Alternative Medicine|March 21, 2006
Dose escalation of a curcuminoid formulationChristopher D Lao, Mack T Ruffin, Daniel Normolle, et al.
The Oncologist|May 13, 2017
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of EncephalitisJames Larkin, Bartosz Chmielowski, Christopher D Lao, et al.
Pigment Cell & Melanoma Research|October 31, 2020
The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanomaVincent T Ma, Stephanie Daignault-Newton, Jessica J Waninger, et al.
Radiation Oncology (London, England)|August 23, 2013
Concurrent whole brain radiotherapy and bortezomib for brain metastasisChristopher D Lao, Judah Friedman, Christina I Tsien, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|February 12, 2020
Sentinel Lymph Node Biopsy in Head and Neck Melanoma: Long-term Outcomes, Prognostic Value, Accuracy, and SafetyJohn E Hanks, Kevin J Kovatch, S Ahmed Ali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Features predicting sentinel lymph node positivity in Merkel cell carcinomaJennifer L Schwartz, Kent A Griffith, Lori Lowe, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
NCCN Guidelines implementation in the multidisciplinary Merkel Cell Carcinoma Program at the University of MichiganJennifer L Schwartz, Sandra L Wong, Scott A McLean, et al.
Cancer Medicine|July 27, 2022
Metastatic melanoma of the heart: Retrospective cohort study and systematic review of prevalence, clinical characteristics, and outcomesAlexander M Balinski, Alexi L Vasbinder, Connor C Kerndt, et al.
Pageof 9

Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
Frontiers in Immunology|July 25, 2022
Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/NivolumabVincent T Ma, Alahendra A Chamila Perera, Yilun Sun, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 13, 2004
Irreversible ototoxicity associated with difluoromethylornithineChristopher D Lao, Patricia Backoff, Lawrence I Shotland, et al.
BMC Complementary and Alternative Medicine|March 21, 2006
Dose escalation of a curcuminoid formulationChristopher D Lao, Mack T Ruffin, Daniel Normolle, et al.
The Oncologist|May 13, 2017
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of EncephalitisJames Larkin, Bartosz Chmielowski, Christopher D Lao, et al.
Pigment Cell & Melanoma Research|October 31, 2020
The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanomaVincent T Ma, Stephanie Daignault-Newton, Jessica J Waninger, et al.
Radiation Oncology (London, England)|August 23, 2013
Concurrent whole brain radiotherapy and bortezomib for brain metastasisChristopher D Lao, Judah Friedman, Christina I Tsien, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|February 12, 2020
Sentinel Lymph Node Biopsy in Head and Neck Melanoma: Long-term Outcomes, Prognostic Value, Accuracy, and SafetyJohn E Hanks, Kevin J Kovatch, S Ahmed Ali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Features predicting sentinel lymph node positivity in Merkel cell carcinomaJennifer L Schwartz, Kent A Griffith, Lori Lowe, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
NCCN Guidelines implementation in the multidisciplinary Merkel Cell Carcinoma Program at the University of MichiganJennifer L Schwartz, Sandra L Wong, Scott A McLean, et al.
Cancer Medicine|July 27, 2022
Metastatic melanoma of the heart: Retrospective cohort study and systematic review of prevalence, clinical characteristics, and outcomesAlexander M Balinski, Alexi L Vasbinder, Connor C Kerndt, et al.
Pageof 9